Akirense Injection is used for the treatment of lymphomas, including diffuse large B-cell lymphoma anaplastic type, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and diffuse large B-cell lymphoma transformed by follicular lymphoma. Akirense Injection is a genetically modified chimeric antigen receptor autologous T (CAR-T) cell targeting human CD19. It is used for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after prior second-line or higher systemic therapy, including diffuse large B-cell lymphoma of the unspecified type, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma-transformed diffuse large B-cell lymphoma. Immunotherapy is one of the therapeutic approaches for cancer, and one of them, chimeric antigen receptor T-cell immunotherapy (CAR-T), has shown revolutionary potential in the treatment of cancer, especially hematological tumors. CAR-T therapy involves modifying the patient’s T-cells in vitro through genetic engineering technology so that they are able to recognize the chimeric antigen receptor (CAR), a receptor for tumor targets, and are subsequently infused back into the patient’s body to exert highly effective anti-tumor effects. The medication should be used under the guidance and supervision of a professional doctor.